SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Traders are closely monitoring the upcoming Federal Reserve meeting, with high expectations for a rate hike as sentiment remains bearish amid concerns over rising Treasury yields, inflation, and oil price volatility. While some participants weigh the potential impact of AI development slowdowns and ongoing geopolitical tensions on market stability, the conversation remains largely focused on the Fed's policy trajectory and its influence on broader market performance.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The conversation is dominated by concerns over rising Treasury yields, which briefly topped 5%, alongside ongoing uncertainty regarding AI-sector development and expectations for a Federal Reserve rate hike. Market participants are debating whether current volatility represents a cooling phase or a potential crash, with a notable split between those reacting to macro headwinds and those betting on a continued market recovery.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as traders speculate on positive guidance updates and clinical progress, following recent healthcare conference appearances and anticipation of upcoming Phase 2 NSCLC trial data. While the stock has seen significant momentum, community sentiment remains focused on the expectation that the company's solid tumor platform and clinical milestones will drive long-term value.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin shares are facing significant volatility as traders debate whether the stock is being manipulated by institutional accumulation or if macroeconomic headwinds and analyst price target downgrades are suppressing the price. The community remains divided, with many bullish investors holding for a recovery toward previous highs, while others express frustration over the stock's inability to maintain gains despite strong fundamentals and cash flow.

ProShares Trust II - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

Traders are actively debating the viability of using UVXY as a volatility hedge amidst geopolitical tensions and economic concerns, with many expressing frustration over its structural decay and perceived lack of correlation to spot VIX. While some market participants are betting on a volatility spike, others warn that its design as a leveraged futures-based product makes it a poor long-term holding prone to constant value erosion.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne shares are trending amid a combination of bullish analyst actions, including price target increases, and community enthusiasm regarding the company's valuation relative to cybersecurity peers. Traders are also actively debating its potential as a takeover candidate due to its AI-native platform and robust cash position.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is experiencing volatility and downward pressure as traders weigh the impact of rising Treasury yields, higher oil prices, and uncertainty regarding Federal Reserve interest rate policy. The community is divided between those interpreting recent price action as a buying opportunity in a long-term uptrend and those concerned that the index is vulnerable to further downside, particularly given its technical weakness and sensitivity to macro headwinds.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending as investors weigh clinical data updates on its oncology pipeline against the company's recent leadership transition, with some traders expressing disappointment over the upcoming departure of the founders while others remain optimistic about the late-stage trial catalysts.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is trending as investors discuss a newly announced partnership with Supermicro to integrate high-density rack-scale servers into the company's Secure AI Factory platform. While some traders are optimistic about the potential for enterprise AI growth, many others remain frustrated by the stock's recent stagnant price action and weak momentum following its earnings report.

Quantinuum Inc. is a quantum computing platform that offers solutions like hardware platforms, developer tools, application libraries and solution-targeted intellectual property (“IP”). The company was founded on January 20, 2026 and is headquartered in Broomfield, CO.

Quantinuum Inc. - Ordinary Shares - Class A

Quantinuum Inc.

Quantinuum is trending following its recent NASDAQ IPO and a new strategic partnership with Oracle to deploy its Helios quantum technology, though community sentiment is divided between optimism regarding its institutional backing and concerns over high valuation relative to current revenue. Traders are also actively discussing the broader quantum sector, fueled by recent U.S. government policy initiatives and federal funding awards for key industry players.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GSK Expects Full-Year Earnings At Top End Of Guidance: CEO Says ‘Confident In Our Long-Term Outlooks’

Equity

GSK now expects turnover growth to be toward the top end of 3% to 5% and core earnings per share growth to be closer to 8% at constant exchange rate.

US FDA Reviewers Highlight Safety Concerns With GSK’s Investigational Cancer Drug: Retail’s On The Fence

FDA reviewers said in briefing documents that the benefit-risk profile of the drug for the treatment of multiple myeloma “remains unclear.”

GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance

A decision by the FDA on the new submission is expected in the first half of 2026.

Fidelity Covington Trust - Fidelity Women's Leadership

Neutral Sentiment

50bps hike

25bps hike

No change

25bps cut

The Federal Reserve's September FOMC meeting concludes Wednesday, September 16, with a rate decision due at 2:00 PM ET, following Tuesday's CPI report that showed inflation still running above the Fed's 2% target. What do you think the Fed decides at this week's FOMC meeting? Vote and explain your reasoning in the comments.

The Fed&#39;s rate decision comes Wednesday at 2PM ET. What do you think happens?

Stocktwits

The Fed's rate decision comes Wednesday at 2PM ET. What do you think happens?

Feed

News

Sentiment

Fundamentals

Info

FDWM Fidelity Covington Trust - Fidelity Women`s Leadership ETF

Latest FDWM News